Biotech | March 20, 2024
Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Ayush is expanding beyond wellness to therapeutic wellness
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
GMM Pfaudler US completes acquisition of MixPro
he company posted total income during Q2 FY24 at Rs. 12.86 crore
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
Good momentum in commercial CDMO business
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Subscribe To Our Newsletter & Stay Updated
